Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received an average rating of “Hold” from the twenty analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $123.33.

A number of brokerages have issued reports on ZBH. Evercore ISI cut their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Truist Financial upped their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Raymond James dropped their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Oppenheimer cut their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Finally, BTIG Research decreased their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its holdings in shares of Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock valued at $701,521,000 after acquiring an additional 722,041 shares during the period. Geode Capital Management LLC boosted its stake in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the period. Van ECK Associates Corp grew its position in Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Zimmer Biomet by 0.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock valued at $277,357,000 after purchasing an additional 9,990 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Zimmer Biomet by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider’s stock valued at $196,523,000 after buying an additional 154,447 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $104.47 on Friday. Zimmer Biomet has a one year low of $101.47 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm’s 50 day moving average price is $108.37 and its 200-day moving average price is $108.17. The firm has a market cap of $20.80 billion, a P/E ratio of 19.86, a P/E/G ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the business posted $1.65 earnings per share. As a group, equities research analysts predict that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.